What question did this study set out to answer?

To describe a severe neurological adverse event following PD-1 inhibitor treatment in a melanoma patient.

March 31, 2026Open Access

Immune-related GFAP-Astrocytopathy under PD-1 Inhibition: A Case Report

Key Points

To describe a severe neurological adverse event following PD-1 inhibitor treatment in a melanoma patient.
Case report of a 53-year-old woman with melanoma
Treatment with the PD-1 inhibitor nivolumab
Analysis of neurological adverse events related to therapy
Patient developed severe neurological symptoms after nivolumab treatment
Identified condition as glial fibrillary acidic protein astrocytopathy
Emphasized need for early diagnosis and intervention in similar cases

Abstract

Immune checkpoint inhibitors have substantially improved survival in advanced melanoma but are also associated with immune-related adverse events.Such events can affect any organ, including the central and peripheral nervous systems.Neurological adverse events are rare and often underrecognized.We report the case of a 53-year-old woman with melanoma who developed a severe neurological adverse event after treatment with the PD-1 inhibitor nivolumab.We describe a rare case of nivolumab-associated glial fibrillary acidic protein astrocytopathy and highlight the diagnostic challenges, therapeutic considerations, and importance of early recognition of these potentially severe neurological adverse events.

Demander à l'IA

Bookmark

View Full Paper